What's Going On With TG Therapeutics Stock Today?
Portfolio Pulse from Vandana Singh
TG Therapeutics Inc's shares have dropped over 40% after reporting Q2 FY23 Briumvi net sales of $16 million in the U.S., missing the consensus of $17.45 million. The company also reported a Q2 EPS loss of $(0.34), up from $(0.30) a year ago, missing the consensus of $(0.25). Concurrently, the company announced an agreement with Neuraxpharm for the ex-U.S. commercialization of Briumvi in RMS, which strengthens the balance sheet with a pro-forma cash balance of approximately $285 million.
August 04, 2023 | 9:46 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TG Therapeutics' shares have dropped significantly due to lower than expected Q2 FY23 Briumvi net sales and a higher EPS loss. However, the agreement with Neuraxpharm for Briumvi's ex-U.S. commercialization could potentially offset some of the negative impact.
The company's shares have dropped due to lower than expected Q2 FY23 Briumvi net sales and a higher EPS loss. These factors indicate a negative short-term impact on the company's stock. However, the agreement with Neuraxpharm for Briumvi's ex-U.S. commercialization, which strengthens the company's balance sheet, could potentially offset some of the negative impact in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100